Hennion & Walsh Asset Management’s Immunovant IMVT Stock Holding History

Hennion & Walsh Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.65M	Buy	120,686 +29,677	+33%	+$904K	0.13%	199
2026 Q1	$2.26M	Buy	91,009 +19,304	+27%	+$500K	0.08%	317
2025 Q4	$1.82M	Buy	+71,705	New	+$1.6M	0.06%	376
2023 Q4	–	Sell	-143,080	Closed	-$5.49M	–	837
2023 Q3	$5.49M	Sell	143,080 -28,248	-16%	-$639K	0.35%	51
2023 Q2	$3.25M	Sell	171,328 -56,228	-25%	-$1.05M	0.19%	131
2023 Q1	$3.53M	Sell	227,556 -26,080	-10%	-$453K	0.22%	120
2022 Q4	$4.5M	Buy	253,636 +23,961	+10%	+$302K	0.28%	88
2022 Q3	$1.28M	Sell	229,675 -6,322	-3%	-$30.9K	0.08%	271
2022 Q2	$920K	Buy	235,997 +14,861	+7%	+$64.2K	0.06%	331
2022 Q1	$1.22M	Buy	221,136 +60,336	+38%	+$376K	0.06%	299
2021 Q4	$1.37M	Buy	160,800 +94,658	+143%	+$781K	0.07%	294
2021 Q3	$575K	Buy	66,142 +22,642	+52%	+$204K	0.03%	477
2021 Q2	$460K	Buy	+43,500	New	+$607K	0.02%	540

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hennion & Walsh Asset Management's IMVT Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Immunovant (IMVT) stake by 33% in Q2 2026, buying an estimated $904K and bringing the position to 120,686 shares worth $4.65M. The position accounts for 0.13% of the portfolio, ranked #199.

Hennion & Walsh Asset Management first reported a position in IMVT in Q2 2021 and has held it in 13 quarters since. The position peaked at $5.49M in Q3 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Hennion & Walsh Asset Management held 120,686 shares of Immunovant worth $4.65M as of Q2 2026.
Hennion & Walsh Asset Management bought 29,677 Immunovant shares in Q2 2026, an estimated $904K.
Immunovant made up 0.13% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #199 holding.
Hennion & Walsh Asset Management first reported a position in Immunovant in Q2 2021 and has held it in 13 quarters since.
Hennion & Walsh Asset Management's Immunovant position peaked at $5.49M in Q3 2023.
227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.